- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Like a bridge over troubled water: keeping the myeloma down en route to CAR-T ; volume:14 ; number:1 ; day:12 ; month:4 ; year:2024 ; pages:1-2 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (12.4.2024), 1-2, 12.2024
- Creator
-
Richter, Joshua
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01049-z
- URN
-
urn:nbn:de:101:1-2406252107148.411513601753
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Richter, Joshua
- SpringerLink (Online service)
Other Objects (12)
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study